Health Care  |  Biotechnology
264.42 -7.255 -2.67%
Stock Price | Jan. 27, 2021, 10:37 a.m.
Bid: 264.05
Ask: 264.55
Prev. Close: 271.67
52 Week Low: 223.25
52 Week High: 374.99
PE Ratio: 8.960092
Dividend Yield: %

Company Summary

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Read more Read less

Recently Viewed Tickers

Free Stocks With Near-Term Upside Potential

5 years ago